FDA approval addresses noninfectious diarrhea in HIV/AIDS patients
FDA?s recent approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, under license from Napo
Pharmaceuticals), 125-mg delayed-release tablets, the first anti-diarrheal drug for HIV/AIDS patients taking
antiretroviral therapy (ART), is a significant step forward in addressing the unmet medical need of people with
HIV/AIDS on ART who experience noninfectious diarrhea, which often can lead to reduced treatment
compliance.
Source: Modern Medicine - Category: Journals (General) Source Type: news
More News: General Medicine | HIV AIDS